New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

about

Ligands for glaucoma-associated myocilin discovered by a generic binding assay Keep your eyes open: challenges and opportunities in ophthalmic therapeutics.

P2860

Q35054336-37ADEEB3-ED28-4348-8C07-AB3213D8597F Q36125998-C954E484-474E-4CA6-AC3E-95D64A044758

P2860

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

Item

http://www.wikidata.org/entity/Q51536319

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@en

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@nl

type

Item

label

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@en

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@nl

prefLabel

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@en

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@nl

P1476

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

@en

P2093

Raquel L Lieberman

http://www.w3.org/2001/XMLSchema#string

Rebecca K Donegan

http://www.w3.org/2001/XMLSchema#string

P2860

One step at a time: endoplasmic reticulum-associated degradation

Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones.

Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function.

Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology.

The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder.

Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma.

Genetic dissection of myocilin glaucoma.

Hsp90 molecular chaperone inhibitors: are we there yet?

Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin.

Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.

P304

2131-2134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4155/FMC.12.132

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23190098

http://www.w3.org/2001/XMLSchema#string

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

about

P2860

P2860

New direction for glaucoma therapeutics: focus on the olfactomedin domain of myocilin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698